Study on High-risk MDS Patients Based on RNA-seq Technology
MDS&RNA-seq
Study on Improving Clinical Diagnosis Classification and Prognosis Evaluation Criteria and Precise Early Intervention Treatment of High-risk MDS Patients Based on RNA-seq Technology
1 other identifier
observational
120
1 country
1
Brief Summary
MDS is a group of malignant cloned blood diseases that originated from hematopoietic stem cells(HSC) or CD34 + progenitor cells and are still incurable. Its main characteristics are the increase of primitive cells in the bone marrow accompanied by a series or multiple developmental abnormalities(pathological hematopoiesis), the reduction of peripheral blood cells, the high risk of conversion to acute myeloid leukemia(AML), and once converted to leukemia, the treatment prognosis is very poor.The bone marrow cells of MDS patients were deeply sequenced by RNA-Seq method. Through differential gene expression analysis, different genes related to the onset and evolution of MDS were selected and their expression levels were analyzed in different subtype MDS patients. To study its significance in clinical classification, prognosis assessment and early intervention treatment, establish a new standard for clinical classification and prognosis evaluation based on genomic classification, clarify early intervention or precise treatment schemes, and significantly prolong the survival of patients, Improving the quality of life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 3, 2019
CompletedFirst Posted
Study publicly available on registry
April 4, 2019
CompletedStudy Start
First participant enrolled
May 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedApril 22, 2019
April 1, 2019
2.7 years
April 3, 2019
April 18, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
RNA-seq
use questionnaire to research whether the target mutation gene combination analyzed by transcription group was consistent with clinical cell morphological diagnosis and disease progression.
2021-2022
Interventions
patients diagnosed as MDS with high risk，aged 18-80，men/wemen
Eligibility Criteria
the population of MDS patients were from the five centers who were visiting the doctor
You may qualify if:
- Patients who meet MDS diagnostic criteria with high risk of IPSS-R
You may not qualify if:
- with no MDS
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
ZJHTCM
Hangzhou, Zhejiang, 310006, China
Study Officials
- STUDY CHAIR
lin s yun, doctor
zjhtcm
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
April 3, 2019
First Posted
April 4, 2019
Study Start
May 1, 2019
Primary Completion
December 31, 2021
Study Completion
December 31, 2022
Last Updated
April 22, 2019
Record last verified: 2019-04